Drug interactions
Temozolomide + Tisagenlecleucel
Severity: Moderate
Temozolomide and Tisagenlecleucel: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Temozolomide causes lymphopenia and myelosuppression, which can impair CAR T-cell expansion and add to infection risk after CAR T therapy. Chemotherapy given near the time of CAR T infusion, other than planned lymphodepletion, may compromise efficacy and safety.
What this interaction means in plain words
Temozolomide and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Temozolomide belongs to Oncology; Tisagenlecleucel belongs to Oncology.
Why it happens
Additive myelosuppressive and lymphotoxic effects of temozolomide may reduce CAR T-cell persistence and increase immunosuppression-related infection.
What to do
Avoid temozolomide in the period around leukapheresis and CAR T infusion unless part of the planned lymphodepletion or bridging regimen. Monitor blood counts and infection signs if given afterward.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Temozolomide and Tisagenlecleucel, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Temozolomide
Other interactions of Tisagenlecleucel
Frequently asked questions
Can I take Temozolomide with Tisagenlecleucel?
MediHelp rates the interaction as moderate. Temozolomide and Tisagenlecleucel can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Temozolomide causes lymphopenia and myelosuppression, which can impair CAR T-cell expansion and add to infection risk after CAR T therapy. Chemotherapy given near the time of CAR T infusion, other than planned lymphodepletion, may compromise efficacy and safety.
How serious is the interaction between Temozolomide and Tisagenlecleucel?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid temozolomide in the period around leukapheresis and CAR T infusion unless part of the planned lymphodepletion or bridging regimen. Monitor blood counts and infection signs if given afterward.
What other medicines interact with Temozolomide?
MediHelp also lists interactions of Temozolomide with, for example, Adenovirus types 4 and 7 live, Belatacept, Deferiprone. The full list is on the Temozolomide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
